Biotechnology Regulatory Inspections Law In Russia.
1. Introduction
Biotechnology regulatory inspections in Russia refer to the legal mechanisms through which government authorities supervise, inspect, investigate and enforce compliance by biotechnology companies, pharmaceutical manufacturers, genetic-engineering laboratories, clinical research organisations, vaccine producers and other entities involved in biological research and commercial production.
Regulatory inspections are important because biotechnology activities can create risks involving:
Human health and patient safety.
Genetically modified organisms (GMOs).
Biological medicines and vaccines.
Recombinant proteins and gene therapies.
Laboratory contamination and biosafety.
Clinical trials and experimental medicines.
Genetic information and biological samples.
Pharmaceutical manufacturing standards.
Environmental release of genetically engineered organisms.
Russia does not regulate all these activities through one comprehensive biotechnology inspection statute. Instead, it uses several federal laws, government regulations and specialised supervisory authorities.
The principal legal framework consists of:
Federal Law No. 248-FZ of 31 July 2020 – State Control (Supervision) and Municipal Control in the Russian Federation.
Federal Law No. 61-FZ of 12 April 2010 – On Circulation of Medicines.
Federal Law No. 86-FZ of 5 June 1996 – On State Regulation in the Field of Genetic Engineering Activities.
Federal Law No. 52-FZ of 30 March 1999 – On Sanitary and Epidemiological Welfare of the Population.
Federal Law No. 99-FZ of 4 May 2011 – On Licensing of Certain Types of Activities.
Federal Law No. 323-FZ of 21 November 2011 – On Fundamentals of Healthcare Protection of Citizens.
Federal Law No. 7-FZ of 10 January 2002 – On Environmental Protection.
The framework combines preventive supervision, documentary verification, on-site inspections, product sampling, laboratory testing, licensing control and administrative enforcement.
mchs.gov.ru+3
2. Federal Law No. 248-FZ: The Principal Inspection Framework
Federal Law No. 248-FZ establishes the general legal structure for state inspections and regulatory supervision in Russia.
It is particularly important for biotechnology companies because it governs how public authorities conduct regulatory inspections, exercise supervisory powers and respond to violations of mandatory requirements.
Its main objectives are:
Preventing regulatory violations.
Protecting public health and environmental safety.
Ensuring compliance with mandatory technical requirements.
Protecting businesses against unlawful regulatory interference.
Establishing procedural safeguards for inspected organisations.
Important inspection mechanisms
The law provides several types of regulatory control activities, including:
| Inspection mechanism | Purpose |
|---|---|
| Documentary verification | Examining licences, manufacturing records and compliance documents |
| On-site inspection | Examining manufacturing facilities and laboratories |
| Inspection visit | Conducting an inspection without prior notification where legally permitted |
| Selective control | Selecting and testing particular products or samples |
| Test purchase | Checking compliance through a controlled purchase |
| Preventive visit | Identifying potential violations and explaining regulatory obligations |
| Monitoring | Assessing compliance with mandatory requirements |
Under Article 70, an inspection visit may involve examining premises, questioning personnel, obtaining written explanations and requesting relevant documents. Such visits may be conducted without advance notification.
The law also regulates the circumstances in which inspections require prosecutorial coordination and establishes exceptions to those requirements.
Application to biotechnology
A Russian biotechnology manufacturing facility may be inspected to verify:
Laboratory cleanliness and biosafety.
Manufacturing procedures.
Equipment maintenance.
Biological material storage.
Quality-control documentation.
Product traceability.
Compliance with mandatory manufacturing standards.
The inspection must have an appropriate legal basis and follow the applicable procedural requirements.
mchs.gov.ru+1
3. Federal Law No. 61-FZ: Inspection of Pharmaceutical and Biotechnological Products
The Federal Law No. 61-FZ on Circulation of Medicines is one of the most important laws governing pharmaceutical biotechnology in Russia.
It covers medicines manufactured domestically and imported into Russia, including relevant biological and biotechnology-based medicinal products.
The regulatory framework includes:
A. Manufacturing inspections
Authorities can examine whether manufacturers comply with applicable manufacturing requirements, including Good Manufacturing Practice (GMP).
Inspection subjects include:
Production of recombinant proteins.
Vaccine manufacturing.
Monoclonal antibody production.
Biological medicinal products.
Sterile pharmaceutical manufacturing.
Quality assurance and quality-control procedures.
B. Clinical-trial inspections
Regulatory authorities may examine whether clinical research is conducted in accordance with applicable legal and ethical requirements.
Inspection subjects include:
Clinical-trial documentation.
Informed consent.
Patient safety.
Adverse-event reporting.
Investigational medicinal products.
Research protocols and monitoring records.
C. Product-quality inspections
Authorities can investigate whether a biological medicinal product meets its registered specifications and applicable quality requirements.
D. Pharmacovigilance inspections
Article 64 of Federal Law No. 61-FZ provides for monitoring the safety of medicines circulating in Russia.
This includes identifying adverse reactions, evaluating safety information and protecting patients against potentially harmful medicines.
Roszdravnadzor is the principal federal supervisory authority for medicine circulation.
roszdravnadzor.gov.ru+2
4. Federal Government Resolution No. 1049 of 29 June 2021
Resolution No. 1049 establishes the regulations governing federal state control and supervision in the circulation of medicinal products.
It operates alongside Federal Law No. 248-FZ and Federal Law No. 61-FZ.
Its regulatory significance includes:
Establishing procedures for pharmaceutical-sector supervision.
Providing for risk-based regulatory control.
Supporting inspections and selective product control.
Establishing supervisory mechanisms for identifying violations.
Providing a framework for enforcement against non-compliant pharmaceutical operators.
For biotechnology companies, this framework is relevant to manufacturers, distributors, importers and other organisations involved in medicinal-product circulation.
The distinction is important: a biotechnology research laboratory is not automatically subject to every pharmaceutical inspection requirement. The applicable regime depends on the activity being performed and the legal classification of the product.
CIS Legislation+1
5. Federal Law No. 86-FZ: Genetic Engineering Inspections
Federal Law No. 86-FZ of 5 June 1996 regulates activities involving genetic engineering in Russia.
It is particularly important for organisations conducting:
Genetic modification.
GMO research.
Genetically engineered organism production.
Genetic engineering experiments.
Production of products using GMOs.
Activities involving environmental release of GMOs.
Article 7: State registration
Article 7 provides for state registration of genetically engineered organisms intended for environmental release and products obtained using or containing such organisms, subject to the statutory requirements and applicable exceptions.
The registration framework is supplemented by Government Resolution No. 839 of 23 September 2013.
Article 12: Legal responsibility
Article 12 establishes responsibility for violations of genetic-engineering legislation, including the use of unregistered GMOs where registration is required and the breach of authorised conditions of use.
Example
Suppose a Russian agricultural biotechnology company develops genetically modified rapeseed.
Regulatory authorities may investigate:
Whether the organism is registered.
Whether the organism is being used for an authorised purpose.
Whether the required safety conditions are observed.
Whether the organism has been released into the environment.
Whether appropriate testing and registration records exist.
The legal consequences may include administrative proceedings, financial penalties and other enforcement measures.
ГАРАНТ+1
6. Regulatory Authorities Responsible for Biotechnology Inspections
Russia uses a multi-agency supervisory system.
| Regulatory authority | Principal inspection responsibilities |
|---|---|
| Roszdravnadzor | Medicines, clinical trials, pharmaceutical circulation and medical products |
| Rospotrebnadzor | Sanitary and epidemiological safety, public-health risks and relevant biological products |
| Rosselkhoznadzor | Agricultural GMOs, veterinary products, seeds and relevant biological materials |
| Ministry of Industry and Trade of Russia | GMP inspections and manufacturing conformity assessments within its assigned competence |
| Ministry of Health of Russia | Medicines policy, registration and regulatory decisions within its statutory competence |
| Federal Service for Supervision of Natural Resources | Environmental compliance and relevant environmental risks |
The division of responsibility is important because one biotechnology operation may trigger more than one inspection regime.
For example, manufacturing a genetically engineered vaccine can involve pharmaceutical manufacturing requirements, sanitary requirements and environmental or biological safety considerations, depending on the activity.
roszdravnadzor.gov.ru+2
7. Types of Regulatory Inspections in Russia
A. Scheduled and risk-based inspections
Authorities assess regulatory risks and determine the appropriate supervisory response under the applicable inspection regime.
A company with a history of serious safety violations may attract greater regulatory attention than an operator with a strong compliance record.
B. Unscheduled inspections
These may be initiated on legally recognised grounds, including information about potential violations or threats to protected interests.
The applicable requirements for authorisation and prosecutorial coordination must be observed.
C. Documentary inspections
Authorities examine records without necessarily conducting a physical inspection of the facility.
Important documents include:
Manufacturing licences.
GMP documentation.
Laboratory reports.
Quality-management records.
Clinical-trial reports.
Product-registration certificates.
Biological-material inventories.
Safety-monitoring records.
D. On-site inspections
Inspectors may examine the actual condition of biotechnology facilities.
This can include cleanrooms, production equipment, laboratories, storage areas and biological-material handling facilities.
E. Selective product control
Authorities may select products or samples for laboratory testing.
This is particularly important for biological medicines because manufacturing defects may affect product purity, potency, sterility and safety.
F. Inspection visits
Article 70 of Law No. 248-FZ permits inspection visits involving physical examination, questioning, written explanations and requests for specified documents. These visits may take place without advance notification and are subject to statutory duration limits.
mchs.gov.ru+2
8. GMP Inspections and Biotechnology Manufacturing
Good Manufacturing Practice is central to the regulation of biotechnology-based medicinal products.
Russian manufacturers must comply with the applicable Russian and Eurasian Economic Union manufacturing requirements.
GMP inspections can examine the following areas:
| Compliance area | What inspectors examine |
|---|---|
| Personnel | Training, qualifications and hygiene |
| Facilities | Cleanroom design and contamination prevention |
| Equipment | Calibration, maintenance and validation |
| Raw materials | Biological-material identification and traceability |
| Manufacturing | Standard operating procedures and process controls |
| Quality control | Testing and laboratory reliability |
| Documentation | Batch records and deviation reports |
| Sterility | Contamination prevention and microbiological testing |
| Storage | Temperature monitoring and stability |
| Corrective action | Investigation of defects and preventive measures |
Example: Recombinant protein manufacturing
Suppose a Russian company produces recombinant insulin.
Inspectors may investigate:
Whether the production organism is properly controlled.
Whether the manufacturing process is validated.
Whether contamination risks are controlled.
Whether purification procedures are documented.
Whether the final product meets quality specifications.
Whether deviations are investigated.
Whether every production batch is traceable.
Failure to maintain appropriate manufacturing controls can result in regulatory enforcement and potentially affect the manufacturer's ability to market its product.
9. Legal Rights of Biotechnology Companies During Inspections
Federal Law No. 248-FZ does not give inspectors unlimited powers.
Biotechnology organisations have procedural protections.
Right to lawful inspection: The company may verify the legal basis and scope of the inspection.
Right to identify inspectors: The organisation may check the inspectors' official credentials and relevant inspection documents.
Right to procedural compliance: Inspectors must comply with the applicable statutory procedures.
Right to challenge findings: The company may contest inspection results, administrative decisions and enforcement measures.
Right to provide evidence: The inspected organisation may submit technical reports, laboratory evidence and written explanations.
Right to appeal: Regulatory decisions can be challenged through the applicable administrative and judicial procedures.
These safeguards are particularly important because biotechnology inspections frequently involve complicated scientific evidence, commercially confidential information and substantial regulatory consequences.
10. Important Russian Case Laws Relating to Regulatory Inspections
Russian biotechnology inspection jurisprudence is relatively specialised. However, courts have considered disputes involving GMO inspections, pharmaceutical manufacturing conformity, registration documents and regulatory enforcement.
The following decisions are particularly relevant.
Case 1. Supreme Court of the Russian Federation – Unregistered Genetically Modified Rapeseed (2023)
Direct biotechnology case
Court: Supreme Court of the Russian Federation.
Decision: 19 September 2023.
Case number: 9-АД23-12-К1.
Subject: Use of genetically modified rapeseed without the required registration.
Facts
An agricultural company used genetically modified rapeseed containing the CP4 EPSPS genetic element on agricultural land in the Nizhny Novgorod region.
During an unscheduled on-site inspection in August 2020, Rosselkhoznadzor identified the use of genetically modified material without the required state registration.
The authorities relied on inspection records, laboratory testing protocols and other documentary evidence.
Legal issues
Whether the company had violated Federal Law No. 86-FZ.
Whether the GMO material required state registration.
Whether laboratory results and inspection records could establish the violation.
Whether administrative responsibility could be imposed.
Judgment
The Supreme Court upheld the earlier decisions finding the company administratively liable.
Legal significance
This case demonstrates that:
GMO registration requirements are enforceable.
Laboratory testing can provide important evidence in inspection proceedings.
Inspection reports and supporting scientific evidence may establish regulatory violations.
Agricultural biotechnology companies must comply with authorised GMO-use conditions.
Relevance to regulatory inspections: This is an important example of judicial review of an inspection-based GMO enforcement action.
ГАРАНТ+1
Case 2. Jodas Expoim – Foreign Pharmaceutical Manufacturing and GMP Compliance (2026)
Pharmaceutical inspection case
Court: Ninth Arbitration Court of Appeal, Moscow.
Decision: 7 September 2026.
Appeal case number: 09АП-25747/2026.
Underlying case: А40-282482/2025.
Parties: Jodas Expoim LLC and the Russian Ministry of Health.
Facts
The dispute concerned the suspension of a medicinal-product registration certificate.
The authorities relied on information concerning an Indian manufacturing facility, including the absence of necessary GMP compliance documentation and concerns about the accuracy of information contained in the product-registration dossier.
Legal issue
Whether the Ministry of Health could suspend a medicine's registration based on concerns about the manufacturer's regulatory compliance and the reliability of registration information.
Decision
The Ninth Arbitration Court of Appeal rejected the company's appeal and upheld the first-instance judgment.
Legal significance
The decision illustrates the importance of:
Accurate manufacturing information.
Valid GMP conformity documentation.
Verification of foreign manufacturing facilities.
Regulatory cooperation between Russian authorities.
Compliance with registration requirements.
Relevance to biotechnology: The same principles are relevant to foreign manufacturers of biological medicines, recombinant proteins and biotechnology-based pharmaceuticals. However, the dispute should not be mistaken for a judgment specifically about a biotechnology manufacturing process.
ГАРАНТ+1
Case 3. Jodas Expoim – GMP Inspection and Suspension of Registration (2026)
Court: Ninth Arbitration Court of Appeal.
Decision: 19 August 2026.
Appeal case number: 09АП-27783/2026.
Underlying case: А40-282474/2025.
Facts
The company challenged a Ministry of Health decision suspending the registration of a medicinal product.
The dispute involved information about an Indian production facility, the absence of valid Eurasian Economic Union GMP conformity documentation and concerns identified during manufacturing inspections.
Judgment
The appellate court rejected the company's appeal and upheld the lower court's decision.
Legal significance
The case illustrates that regulatory authorities may rely on manufacturing inspection findings and deficiencies in GMP conformity documentation when taking decisions affecting pharmaceutical registration.
It also highlights the importance of submitting accurate manufacturing information and maintaining appropriate evidence of regulatory conformity.
ГАРАНТ+1
Case 4. Jodas Expoim – Cancellation of Pharmaceutical Registration (2026)
Court: Ninth Arbitration Court of Appeal.
Decision: 27 July 2026.
Appeal case number: 09АП-25171/2026.
Underlying case: А40-316317/2025.
Facts
The dispute concerned the cancellation of a medicinal-product registration based on allegedly inaccurate information in the registration dossier.
Information from Roszdravnadzor and the Ministry of Industry and Trade concerning the foreign manufacturing facility and its regulatory compliance formed part of the evidentiary background.
Judgment
The appellate court upheld the lower court's decision and rejected the company's challenge.
Legal significance
The case demonstrates the regulatory importance of truthful manufacturing declarations, inspection findings and valid conformity documentation.
Biotechnology application: Companies seeking registration of biological medicinal products must ensure that manufacturing information and supporting compliance documents are accurate and verifiable.
ГАРАНТ+1
11. Administrative and Legal Consequences of Inspection Violations
When biotechnology companies violate mandatory regulatory requirements, several consequences may follow.
| Violation | Possible legal consequence |
|---|---|
| Unregistered GMO use | Administrative liability under applicable GMO legislation |
| Pharmaceutical manufacturing violations | Corrective orders and administrative enforcement |
| Serious GMP deficiencies | Regulatory action affecting manufacturing or product registration |
| Unsafe biological products | Restriction or withdrawal from circulation |
| Clinical-trial violations | Regulatory action against the responsible organisation |
| Sanitary violations | Administrative fines or suspension where legally authorised |
| Environmental violations | Environmental enforcement and potential liability |
Relevant provisions include:
Article 12 of Federal Law No. 86-FZ.
Article 64 of Federal Law No. 61-FZ.
Article 6.3 of the Russian Code of Administrative Offences.
Article 6.3.1 of the Code of Administrative Offences, where its specific GMO-related requirements apply.
Article 14.43 of the Code of Administrative Offences concerning violations of technical regulations, where applicable.
The exact offence and penalty depend on the nature of the violation, the applicable statutory provision and the evidence established in the proceedings.
12. Judicial Remedies Against Unlawful Regulatory Inspections
A biotechnology company that considers an inspection unlawful can pursue legal remedies.
A. Administrative appeal
The company may challenge regulatory decisions through the applicable administrative appeal procedure under Federal Law No. 248-FZ.
B. Arbitration court proceedings
Commercial organisations and individual entrepreneurs can generally challenge decisions and actions of public authorities before arbitration courts under Chapter 24 of the Russian Arbitration Procedure Code.
C. Challenge to inspection evidence
A company may dispute:
Improperly collected samples.
Defective laboratory procedures.
Inaccurate inspection reports.
Evidence obtained outside the authorised inspection scope.
Procedural violations.
Incorrect interpretation of mandatory requirements.
D. Challenge to enforcement measures
A company may challenge an administrative fine, corrective order, suspension decision or other regulatory action through the appropriate judicial procedure.
An important principle is that scientific disagreement alone does not automatically invalidate an inspection. The company must establish the relevant factual, legal or procedural defect.
13. Major Legal Challenges in Russian Biotechnology Inspections
1. Scientific complexity
Inspectors must evaluate complex technologies, including gene editing, recombinant DNA, cell therapies and biological manufacturing processes.
2. GMP compliance
Biological medicines require specialised manufacturing controls. Small deviations can potentially affect product quality and patient safety.
3. Foreign manufacturing facilities
Russian authorities may need to evaluate foreign inspection reports, GMP certificates and manufacturing documentation.
4. Laboratory evidence
Disputes can arise over sampling procedures, testing methods, contamination and the interpretation of genetic-analysis results.
5. Commercial confidentiality
Biotechnology inspections may involve confidential manufacturing processes, genetic information and proprietary research.
6. Overlapping regulatory jurisdictions
The involvement of multiple supervisory authorities can create uncertainty regarding inspection responsibilities and compliance requirements.
7. Judicial review
Companies may face difficulties challenging technical findings when they lack independent scientific evidence or sufficient documentation.
14. Compliance Requirements for Russian Biotechnology Companies
A biotechnology organisation should establish a comprehensive inspection-readiness programme.
The following checklist provides a practical framework.
Biotechnology regulatory inspection checklist
0 of 12 completed
0%
Maintain all required licences and product registrations
Maintain applicable GMP and quality-management documentation
Prepare standard operating procedures (SOPs)
Maintain biological-material traceability records
Validate manufacturing and laboratory processes
Maintain equipment calibration and maintenance records
Document contamination-control procedures
Maintain clinical-trial and informed-consent documentation where applicable
Record adverse events and safety reports
Maintain GMO registration and authorised-use documentation where required
Prepare inspection reports and corrective-action records
Establish procedures for responding to regulatory notices
15. Relationship Between Russian and Eurasian Economic Union Law
Russian biotechnology inspections must also be understood within the wider framework of the Eurasian Economic Union (EAEU).
The EAEU includes Russia, Armenia, Belarus, Kazakhstan and Kyrgyzstan.
Its common regulatory framework is relevant to pharmaceutical manufacturing, GMP inspections and medicinal-product registration.
Important regulatory instruments include:
EAEU Good Manufacturing Practice requirements.
EAEU Rules for Registration and Examination of Medicinal Products.
Common pharmaceutical-market requirements.
EAEU technical regulations relevant to biological and food products.
Consequently, a biotechnology company operating in Russia and exporting biological medicines to other EAEU countries may need to satisfy both Russian national requirements and applicable EAEU requirements.
This is particularly important for manufacturers seeking recognition of manufacturing conformity and pharmaceutical registration across the common market.
16. Conclusion
Biotechnology regulatory inspections in Russia are governed by a multi-layered legal system involving Federal Law No. 248-FZ, Federal Law No. 61-FZ, Federal Law No. 86-FZ and related sanitary, environmental and licensing legislation.
Roszdravnadzor, Rosselkhoznadzor, Rospotrebnadzor and other competent authorities exercise different supervisory responsibilities depending on the nature of the biotechnology activity.
The Supreme Court's 2023 GMO decision, Case No. 9-АД23-12-К1, demonstrates the enforceability of GMO registration and authorised-use requirements. The 2026 Jodas Expoim arbitration disputes illustrate the importance of GMP inspections, manufacturing conformity and accurate pharmaceutical registration information.
The central legal principle is that biotechnology companies must maintain scientific safety, manufacturing quality, registration compliance and accurate regulatory documentation while retaining their statutory rights to challenge unlawful inspection procedures and enforcement decisions.
17. Important Legislation and Research References
| Legislation | Regulatory subject |
|---|---|
| Federal Law No. 248-FZ (2020) | State inspections and supervision |
| Federal Law No. 61-FZ (2010) | Medicines and biological pharmaceuticals |
| Federal Law No. 86-FZ (1996) | Genetic engineering and GMOs |
| Federal Law No. 52-FZ (1999) | Sanitary and epidemiological safety |
| Federal Law No. 99-FZ (2011) | Licensing |
| Federal Law No. 323-FZ (2011) | Healthcare protection |
| Federal Law No. 7-FZ (2002) | Environmental protection |
| Government Resolution No. 1049 (2021) | Pharmaceutical state supervision |
| Government Resolution No. 839 (2013) | GMO registration |
Useful primary and institutional sources
Federal Law No. 248-FZ – State Control and Supervision.
Roszdravnadzor – Federal State Control over Medicines.
Government Resolution No. 1049.
Supreme Court GMO decision, 19 September 2023.
Jodas Expoim appellate decision, 7 September 2026.
Jodas Expoim appellate decision, 19 August 2026.
Library of Congress – Russian GMO Regulatory Framework.
Research qualification: The cited GMO Supreme Court decision is a direct biotechnology enforcement case. The Jodas Expoim cases concern pharmaceutical manufacturing and GMP compliance rather than biotechnology alone. They are relevant by analogy to biotechnology-based medicinal products. The decisions discussed here should not be interpreted as establishing a single comprehensive judicial doctrine on Russian biotechnology inspections.

comments